GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medigen Vaccine Biologics Corp (ROCO:6547) » Definitions » Debt-to-Revenue

Medigen Vaccine Biologics (ROCO:6547) Debt-to-Revenue : 0.66 (As of Dec. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Medigen Vaccine Biologics Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Medigen Vaccine Biologics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was NT$39.3 Mil. Medigen Vaccine Biologics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was NT$299.7 Mil. Medigen Vaccine Biologics's annualized Revenue for the quarter that ended in Dec. 2024 was NT$515.2 Mil. Medigen Vaccine Biologics's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 was 0.66.


Medigen Vaccine Biologics Debt-to-Revenue Historical Data

The historical data trend for Medigen Vaccine Biologics's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medigen Vaccine Biologics Debt-to-Revenue Chart

Medigen Vaccine Biologics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.37 0.06 5.36 5.07 0.56

Medigen Vaccine Biologics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.88 8.44 0.41 0.30 0.66

Competitive Comparison of Medigen Vaccine Biologics's Debt-to-Revenue

For the Biotechnology subindustry, Medigen Vaccine Biologics's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medigen Vaccine Biologics's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medigen Vaccine Biologics's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Medigen Vaccine Biologics's Debt-to-Revenue falls into.


;
;

Medigen Vaccine Biologics Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Medigen Vaccine Biologics's Debt-to-Revenue for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(39.262 + 299.701) / 605.637
=0.56

Medigen Vaccine Biologics's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(39.262 + 299.701) / 515.22
=0.66

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2024) Revenue data.


Medigen Vaccine Biologics Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Medigen Vaccine Biologics's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Medigen Vaccine Biologics Business Description

Traded in Other Exchanges
N/A
Address
No. 16, Neihu Road, Lane 120, Floor 7, Section 1, Neihu District, Taipei, TWN, 11493
Medigen Vaccine Biologics Corp is a biopharmaceutical company focusing on developing and producing vaccines and biologics. It is engaged in developing IP-protected cell-culture technologies for vaccine manufacturing. The company develops vaccines and affordable biosimilars to prevent regional infectious diseases. The group generates revenue from manufacturing and selling a range of Covid-19 vaccines and Covid-19 test kits and provides technical services on cellular therapy product quality and cell culture tests.

Medigen Vaccine Biologics Headlines

No Headlines